T2 Biosystems Announces Meta-analysis of Controlled Studies in Peer-Reviewed Medical Journal Highlighting the Benefits of T2MR Technology Compared to Blood Culture
LEXINGTON, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that Expert Review of Medical Devices, a peer-reviewed medical journal, published meta-analysis findings confirming that utilization of T2 Biosystems’ Magnetic Resonance (T2MR®) technology for identification of bloodstream infections (BSIs) provides faster time to detection, faster transition to targeted microbial therapy, faster de-escalation of empirical therapy, and shorter Intensive Care Unit (ICU) and hospital stay, and with comparable mortality rate versus the current blood culture standard.
Study authors of the meta-analysis, “Antimicrobial and Resource Utilization with T2 Magnetic Resonance for Rapid Diagnosis of Bloodstream Infections: Systematic Review with Meta-analysis of Controlled Studies,” systematically searched MEDLINE, EMBASE, and CENTRAL for randomized trials or observational controlled studies of patients with suspected BSIs receiving a diagnosis with T2MR or blood culture, ultimately including 14 studies. Key meta-analysis results include:
“This analysis reinforces the clinical benefits of our technology compared to blood culture for BSI diagnosis and management,” said Aparna Ahuja MD, Chief Medical Officer at T2 Biosystems. “This provides compelling evidence that T2MR technology enables faster targeted treatment which can have a significant positive impact on patient care, antimicrobial stewardship and cost management for hospitals that adopt it as part of their sepsis protocols.”
The time-savings associated with T2MR technology provide meaningful clinical and economic value for patients and hospitals. As identified by the meta-analysis, ICU stay and hospital stay were, on average, five days shorter in patients receiving a diagnosis with the T2MR panels as compared to blood cultures. The authors conclude that in addition to significant clinical improvements and efficiencies, this could theoretically reduce hospital costs by up to $25,000 per patient tested.
About T2 Biosystems
IVR in the COVID Age: Keeping Your Telephony Messaging Fluid